Literature DB >> 26443595

Progress toward improved therapies for inborn errors of metabolism.

Virginia Maria Ginocchio1, Nicola Brunetti-Pierri2.   

Abstract

Because of their prevalence, severity and lack of effective treatments, inborn errors of metabolism need novel and more effective therapeutic approaches. The opportunity for an early treatment coming from expanded newborn screening has made this need even more urgent. To meet this demand, a growing number of novel treatments are entering in the phase of clinical development. Strategies to overcome the detrimental consequences of the enzyme deficiencies responsible for inborn errors of metabolism have been focused on multiple fronts at the levels of the gene, RNA, protein and whole cell. These strategies have been accomplished using a wide spectrum of approaches ranging from small molecules to enzyme replacement therapy, cell and gene therapy. The applications of new technologies in the field of inborn errors of metabolism, such as genome editing, RNA interference and cell reprogramming, along with progress in pre-existing strategies, such as gene therapy or cell transplantation, have tremendous potential for clinical translation.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2015        PMID: 26443595     DOI: 10.1093/hmg/ddv418

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  2 in total

Review 1.  Aldehyde dehydrogenase 2 in aplastic anemia, Fanconi anemia and hematopoietic stem cells.

Authors:  Lauren D Van Wassenhove; Daria Mochly-Rosen; Kenneth I Weinberg
Journal:  Mol Genet Metab       Date:  2016-07-15       Impact factor: 4.797

2.  DDIEM: drug database for inborn errors of metabolism.

Authors:  Marwa Abdelhakim; Eunice McMurray; Ali Raza Syed; Senay Kafkas; Allan Anthony Kamau; Paul N Schofield; Robert Hoehndorf
Journal:  Orphanet J Rare Dis       Date:  2020-06-11       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.